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Summary
DNA and RNA stimulate the mammalian innate im-
mune system through activation of Toll-like receptors
(TLRs). DNA containing methylated CpG motifs, how-
ever, is not stimulatory. Selected nucleosides in natu-
rally occurring RNA are also methylated or otherwise
modified, but the immunomodulatory effects of these
alterations remain untested. We show that RNA sig-
nals through human TLR3, TLR7, and TLR8, but incor-
poration of modified nucleosides m5C, m6A, m5U,
s2U, or pseudouridine ablates activity. Dendritic cells
(DCs) exposed to such modified RNA express signifi-
cantly less cytokines and activation markers than
those treated with unmodified RNA. DCs and TLR-
expressing cells are potently activated by bacterial
and mitochondrial RNA, but not by mammalian total
RNA, which is abundant in modified nucleosides. We
conclude that nucleoside modifications suppress the
potential of RNA to activate DCs. The innate immune
system may therefore detect RNA lacking nucleoside
modification as a means of selectively responding to
bacteria or necrotic tissue.
Introduction
The innate immune system is the first line of defense
against invading pathogens (Medzhitov, 2001). This
system utilizes TLRs to recognize conserved pathogen-
associated molecular patterns and orchestrate the initi-
ation of immune responses. TLRs are germ line-encoded
signaling receptors with extracellular leucine-rich re-
peats and intracellular signaling domains. In humans,
ten distinct TLR family members have been identified,
and corresponding microbial ligands for most have
been identified. Several TLRs recognize and respond to
nucleic acids. DNA containing unmethylated CpG mo-
tifs, characteristic of bacterial and viral DNA, activate
TLR9 (Hemmi et al., 2000). Double-stranded (ds)RNA, a
frequent viral constituent, has been shown to activate
TLR3 (Alexopoulou et al., 2001; Wang et al., 2004), sin-
gle-stranded (ss)RNA activates mouse TLR7 (Diebold
et al., 2004), and RNA oligonucleotides with phos-
phorothioate internucleotide linkages are ligands of hu-
man TLR8 (Heil et al., 2004). Based on structural and
sequence similarities, TLR7, TLR8, and TLR9 form a
subfamily. Activation of these receptors depends upon
endosomal acidification and leads to interferon produc-
tion. Human TLR7 and TLR8 are stimulated by the syn-*Correspondence: kariko@mail.med.upenn.eduthetic antiviral compound R-848 (Jurk et al., 2002), but
a natural ligand has not been identified.
It has been known for decades that selected DNA
and RNA molecules have the unique property to acti-
vate the immune system. It was discovered only re-
cently that secretion of interferon in response to DNA
is mediated by unmethylated CpG motifs acting upon
TLR9 present on immune cells (Hemmi et al., 2000). For
years, bacterial and mammalian DNA were portrayed
as having the same chemical structure, which ham-
pered the understanding of why only bacterial, but not
mammalian, DNA is immunogenic. Recently, however,
the sequence and structural microheterogeneity of
DNA has come to be appreciated. For example, methyl-
ated cytidine in CpG motifs of DNA has proven to be
the structural basis of recognition for the innate im-
mune system. In light of this finding and given that mul-
tiple TLRs respond to RNA, a question emerges as to
whether the immunogenicity of RNA is under the con-
trol of similar types of modification. This possibility is
not unreasonable given that RNA undergoes nearly one
hundred different nucleoside modifications (Rozenski
et al., 1999). Importantly, the extent and quality of RNA
modifications depend on the RNA subtype and corre-
late directly with the evolutionary level of the organism
from which the RNA is isolated. Ribosomal RNA, the
major constituent (w80%) of cellular RNA, contains sig-
nificantly more nucleoside modifications when ob-
tained from mammalian cells versus bacteria. Human
rRNA, for example, has ten times more pseudouridine
(Ψ) and 25 times more 2#-O-methylated nucleosides
than bacterial rRNA, whereas rRNA from mitochondria,
an organelle that is a remnant of eubacteria (Margulis
and Chapman, 1998), has very few modifications (Bach-
ellerie and Cavaille, 1998). Transfer RNA is the most heav-
ily modified subgroup of RNA. In mammalian tRNAs, up
to 25% of the nucleosides are modified, whereas there
are significantly less modifications in prokaryotic tRNAs.
Bacterial mRNA contains no nucleoside modifications,
whereas mammalian mRNAs have modified nucleo-
sides such as 5-methylcytidine (m5C), N6-methyladen-
osine (m6A), inosine and many 2#-O-methylated nucle-
osides in addition to N7-methylguanosine (m7G), which
is part of the 5#-terminal cap (Bokar and Rottman,
1998). The presence of modified nucleosides was also
demonstrated in the internal regions of many viral
RNAs including influenza, adeno, and herpes simplex;
surprisingly, modified nucleosides were more frequent
in viral than in cellular mRNAs (Bokar and Rottman,
1998). A substantial number of nucleoside modifica-
tions are uniquely present in either bacterial or mam-
malian RNA, thus providing an additional molecular fea-
ture for immune cells to discriminate between microbial
and host RNA. Considering that cells usually contain
five to ten times more RNA than DNA, presence of such
distinctive characteristics on RNA could make them a
rich molecular source for sampling by the immune sys-
tem, a notion becoming evident by the identification of
multiple TLRs signaling in response to RNA. The role
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potential of RNA, however, is not known.
In recent years, we have investigated the immuno-
modulatory effect of RNA on human DCs. These studies
demonstrated that in vitro-transcribed RNA activates/
matures DCs (Weissman et al., 2000) partially by a
mechanism in which double-stranded regions of the
RNA signal through TLR3 (Kariko et al., 2004). Recently,
it was noted that in vitro transcripts, or total RNA de-
rived from bacteria, but not from eukaryotic cells, can
prime DCs for high-level IL-12 secretion (Koski et al.,
2004). The molecular basis for the discrimination be-
tween these various RNAs is not fully understood. In
this report, we sought to determine whether naturally
occurring nucleoside modifications modulate the im-
munostimulatory potential of RNA and the role TLRs
might play in this process.
Results
Naturally Occurring RNAs Are Not Equally Potent
Activators of DCs
We recently demonstrated that RNA transcribed in vitro
or released from necrotic mammalian cells activates
Fhuman DCs (Kariko et al., 2004). In an independent
rstudy, we also determined that although in vitro-tran-
Hscribed RNAs are effective, eukaryotic mRNA and tRNA
w
did not stimulate cultured human DCs (Koski et al., a
2004). This finding prompted us to investigate the im- l
munostimulatory potential of different cellular RNA sub- (
mtypes. The objective was to identify the likely RNA com-
sponents from necrotic cells that activated DCs in the
moriginal experimental setting. We first isolated RNA
from different subcellular compartments (cytoplasm,
nucleus, and mitochondria). These RNA isolates as well
ras total RNA, tRNA, and polyA-tail-selected mRNA, all
tfrom mammalian sources, were complexed to lipofectin
tand added to monocyte-derived DCs (MDDCs) gener-
bated with GM-CSF and IL-4. We determined that mam-
fmalian total, nuclear, and cytoplasmic RNA and mRNA
wall induced TNF-α secretion, although at very low levels
trelative to RNA synthesized in vitro by T7 RNA polymer-
ase (RNAP) (Figure 1). Interestingly, mammalian tRNA
did not induce any detectable level of TNF-α, whereas I
Tmitochondrial (mt)RNA was the most potent RNA type
to stimulate MDDCs. Considering that mtRNA shares M
Nmore characteristics with bacterial RNA than with other
mammalian RNA types, it was not surprising to find that c
cbacterial total RNA was also a very potent activator of
MDDCs (Figure 1). Bacterial tRNA, which is modified a
obut to a lesser extent than mammalian tRNA, induced a
low level of TNF-α, whereas tRNAs from other sources w
w(yeast, wheat germ, and bovine) were nonstimulatory
(Figure 1 and data not shown). Similar results were ob- r
iserved when RNAs from other mammalian sources
were tested as well as when the RNA repertoires were t
Ranalyzed by using GM-CSF + IFN-α-generated MDDCs
(data not shown). When RNA samples were digested t
nwith Benzonase, capable of cleaving both ssRNA and
dsRNA, RNA signaling was abolished in MDDCs, verify- a
oing that RNA is the active component that triggers
TNF-α secretion (Figure 1). These findings demonstrate l
nthat from the view of immunostimulation not all natu-igure 1. Production of TNF-α by MDDCs Transfected with Natu-
al RNA
uman MDDCs were incubated with lipofectin alone, or complexed
ith R-848 (1 g/ml), or RNA (5 g/ml) from 293 cells (total, nuclear,
nd cytoplasmic RNAs), mouse heart (polyA+ mRNA), human plate-
et mitochondrial RNA, bovine tRNA, bacterial tRNA, and total RNA
E. coli) with or without RNase digestion. After 8 hr, TNF-α was
easured in the supernatants by ELISA. Mean values ± SEM are
hown. The results are representative of three independent experi-
ents.ally occurring RNAs are equal. The activation poten-
ials of RNAs seem to have an inverse correlation with
he extent of their nucleoside modification, because
acterial RNA and mtRNA that contain only a few modi-
ications are the most potent activators of DCs,
hereas extremely modified tRNAs have little to no ac-
ivity.
n Vitro-Transcribed RNA Stimulates Human TLR3,
LR7, and TLR8, but Most of the Nucleoside-
odified RNAs Are Not Stimulatory
aturally, all RNA is synthesized from four basic ribonu-
leotides, ATP, CTP, UTP and GTP, but some of the in-
orporated nucleosides are modified posttranscription-
lly in almost all types of RNA. The extent and nature
f modifications vary and depend on the RNA type as
ell as the evolutionary level of the organism from
here the RNA is derived. Because findings with natu-
al RNA suggested that nucleoside modifications might
nfluence the ability of RNA to activate DCs, we set out
o further investigate this possibility. First, to obtain
NA with selected modifications, we performed in vitro
ranscription reactions in which one or two of the four
ucleotide triphosphates (NTPs) were substituted with
corresponding nucleoside-modified NTP. Several sets
f RNA with different primary sequences ranging in
ength between 0.7 and 1.9 kb and containing either
one, one, or two types of modified nucleosides were
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167transcribed. Modified RNAs analyzed by denaturing gel
electrophoresis were indistinguishable from their non-
modified counterparts in such that all were intact and
migrated as expected based on their sizes (Figure 2A).
We and others recently demonstrated that in vitro-
transcribed RNA activates human TLR3 (Kariko et al.,
2004) and murine TLR7 (Diebold et al., 2004), whereas
chemically synthesized oligoribonucleotides (ORNs)
stimulate murine TLR7 and human TLR8 (Heil et al.,
2004). Therefore, to determine whether modification of
nucleosides influences the RNA-mediated activation of
TLRs, we utilized human 293 cell lines stably trans-
formed to express human TLR3, TLR7, or TLR8 and
monitored TLR activation through IL-8 release. First,
TLR3-transformed cells were treated with lipofectin-
complexed RNA (RNA-1571, RNA-730, or RNA-1866)
and, as expected based on previous studies (Kariko et
al., 2004), high levels of IL-8 secretion were measured.
RNA containing m6A or s2U modifications did not in-
duce detectable levels of IL-8 (Figure 2B and data not
shown). The presence of other nucleoside modifica-
tions such as m5C, m5U, Ψ, or m5C/Ψ in the RNA had
a less remarkable suppression or no effect at all on the
potential of RNA to activate TLR3 (Figure 2B).
We previously noted that the parental 293 cells ex-
press a low level of endogenous TLR3 (Kariko et al.,
2004). Therefore, the unwanted expression of endoge-
nous TLR3 was eliminated by stably transfecting the
293-hTLR8 cell line with a plasmid expressing TLR3-Figure 2. TLR-Dependent Activation by RNA
(A) Aliquots (1 g) of in vitro-transcribed
RNA-1571 without (none) or with m5C, m6A,
Ψ, m5U, or s2U nucleoside modifications
were analyzed on denaturing agarose gel fol-
lowed by ethidium bromide-staining and UV
illumination.
(B) 293 cells stably expressing human TLR3,
TLR7, TLR8, and control vectors were
treated with lipofectin alone or complexed
with R-848 (1 g/ml) or the indicated RNA (5
g/ml). Modified nucleosides present in
RNA-730 and RNA-1571 are noted. 293-
ELAM-luc cells were used as control cells,
but other controls gave similar results.
(C) CpG ODN-2006 (5 g/ml), LPS (1.0 g/
ml), and RNA isolates were obtained from rat
liver, mouse cell line (TUBO) and human
spleen (total), or human platelet mitochon-
drial RNA, or from two different E. coli
sources. 293-hTLR9 cells served as control.
After 8 hr, IL-8 was measured in the superna-
tants by ELISA.
Mean values ± SEM are shown. Cell lines
transformed to express hTLR3-targeted siRNA
are indicated with an asterisk. The results are
representative of four independent experi-
ments. N.D., not determined.specific short hairpin (sh)RNA. This newly generated
cell line, which did not respond to poly(I):(C), was used
for further study (Figure 2B). When the 293-hTLR8 cells
expressing TLR3-targeted shRNA were transfected with
in vitro-transcribed RNAs, they secreted large amounts
of IL-8; however, transfecting RNA containing any of
the nucleoside modifications did not stimulate these
cells (Figure 2B). In some experiments, we observed
that m6A modification in the RNA permitted a limited
amount of IL-8 release. Control cells (293, 293-pUNO
null, 293-TLR3-sh, and 293-hTLR9) did not respond to
RNA transfection. (Figures 2B and 2C and data not
shown). To rule out that clonal artifacts were responsi-
ble for RNA-induced stimulation, at least three separate
clones for each TLR-expressing cell line were analyzed
and gave similar results.
In a previous study, human TLR8, but not human
TLR7, was shown to signal in response to guanosine-
and uridine-rich ssRNA oligomers with phosphorothi-
oate internucleotide linkages (Heil et al., 2004). Given
that TLR7 and TLR8 share R-848 as a ligand, we sought
to determine whether long RNA with natural phospho-
diester internucleotide linkages was also a shared li-
gand for these human TLRs. All of the in vitro-tran-
scribed RNAs induced IL-8 at levels comparable to
R-848 when transfected into 293-hTLR7 cells express-
ing TLR3-targeted shRNA. However, transfection of
RNA containing modified nucleosides resulted in no in-
duction of IL-8 (Figure 2B). Experiments performed on
Immunity
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gave similar results. Overall, these experiments demon- t
strate that RNA activates human TLR3, TLR7, and TLR8 w
and that nucleoside modifications limit the capacity of p
RNA to stimulate these TLRs. Specifically, m6A and s2U b
modifications suppress the ability of RNA to stimulate t
TLR3, whereas m6A, m5C, m5U, s2U, and Ψ modifica- a
tions block stimulation of TLR7 and TLR8. t
In the next set of experiments, RNAs isolated from T
natural sources were tested. First, RNA from different w
mammalian species were transfected into 293 cells sta- w
bly expressing human TLR3, TLR7, or TLR8 (TLR7 and n
TLR8 cell lines also expressed TLR3-targeted shRNA). m
None of these RNAs induced substantial IL-8 secretion. t
However, bacterial total RNA, obtained from two dif- p
ferent E. coli sources, induced robust IL-8 secretion a
(Figure 2C). These results and additional experimental 2
evidence, first that bacterial RNA transfected to 293- e
hTLR9 did not induce IL-8 secretion (Figure 2C) and m
second that LPS and unmethylated DNA (CpG ODN), b
the potential contaminants in bacterial RNA isolates, s
did not activate the tested TLRs (Figure 2C), together t
indicate that bacterial RNA is an activator of TLR3, h
TLR7, and TLR8. Mitochondrial RNA isolated from hu- m
man platelets also stimulated human TLR8, but not i
TLR3 or TLR7 (Figure 2C). Collectively, these data di-
rectly demonstrate that RNA that is scarce in modified i
nucleosides, such as those isolated from bacteria or s
mitochondria, stimulate selected human TLRs, whereas t
total mammalian RNA abundant in nucleoside modifi- C
cations are non- or minimally stimulatory. t
R
Modified Nucleosides Reduce the Capacity of RNA d
to Induce Cytokine Secretion and Activation a
Marker Expression by DCs R
RNAs containing modified or unmodified nucleosides i
were tested on DCs. A representative data set obtained
with MDDCs and IFN-α-generated MDDCs (Figures 3A S
and 3B) demonstrates that nucleoside modifications di- Iminish the ability of RNA to induce TNF-α and IL-12 Nsecretion. Results were similar (data not shown) when
Tother sets of RNA with the same base modifications but
cdifferent primary sequences and lengths were tested or
qwhen the RNAs were further modified by adding 5# cap
mstructure and/or 3# end polyA-tail or by removing the
t5# triphosphate moiety, which was previously reported
mto promote interferon production (Kim et al., 2004).
bRNAs of different length and sequence induced varying
tamounts of TNF-α from DCs, typically less than a
s2-fold difference (Figure 3C). However, we detected
wmore variability when MDDCs from different donors
rwere used. In most of the experiments, MDDCs re-
vsponded to RNA treatment as presented in Figure 3A,
abut w25% of the time, the presence of m6A reduced
uthe RNA-mediated MDDC activation more potently than
im5C or Ψ did. Under those circumstances, the relative
qsensitivity of MDDCs to poly(I):(C) and R-848 treat-
wments also differed. (Figure S1 available in the Supple-
tmental Data with this article online). This variability was
anot observed for primary DCs described below. By
tusing Northern analysis we also confirmed that cellular
iuptake and stability of the transfected RNAs were not
Rinfluenced by the nucleoside modifications (data not
shown). tTo determine whether primary blood DCs responded
o RNA in a manner similar to cytokine-generated DCs,
e purified primary monocytoid (DC1, BDCA-1+) and
lasmacytoid (DC2, BDCA-4+) DCs from peripheral
lood. Both cell types produced TNF-α when exposed
o R-848, but only DC1 responded to poly(I):(C), though
t a very low level, demonstrating absence of TLR3 ac-
ivity in DC2. Transfection of in vitro transcripts induced
NF-α secretion in both DC1 and DC2 (Figure 3D). Data
ith modified RNA revealed that only transcripts in
hich uridine was replaced with m5U, Ψ, or s2U were
ot stimulatory, whereas RNAs containing m5C and
6A were almost as potent inducers of cytokines as
he corresponding unmodified RNAs. This was unex-
ected because DC2s do not express TLR3 or TLR8
nd as such should resemble the response observed in
93-hTLR7 cells. To determine whether m5C and m6A
xert a dominant stimulatory effect, transcripts with
6A/Ψ double modification were tested and found to
e nonstimulatory, whereas the mixture of RNA with
ingle type of modification (m6A + Ψ) was a potent cy-
okine inducer. This suggested that primary DCs likely
ave an additional RNA signaling entity that recognizes
5C- and m6A-modified RNA and whose signaling is
nhibited by modification of U residues.
FACS analysis of MDDCs treated with RNA-1571 and
ts modified versions revealed that modified nucleo-
ides such as m5C, m6A, Ψ, s2U, and m6A/Ψ decrease
he ability of RNAs to induce cell surface expression of
D80, CD83, CD86, and MHC class II (Figure 4). Collec-
ively, these results demonstrate that the capacity of
NA to induce DCs to mature and secrete cytokines
epends on the subtype of DC as well as on the char-
cteristics of nucleoside modification present in the
NA with the general tendency of modifications block-
ng stimulation.
uppression of RNA-Mediated Immune Stimulation
s Proportional to the Number of Modified
ucleosides Present in RNA
o ideally define the importance of nucleoside modifi-
ations that are components of natural RNA would re-
uire the construction of RNAs in vitro that accurately
odel the extent and diversity of nucleoside modifica-
ions of native RNAs and the ability to selectively re-
ove modifications present in natural RNA isolates,
oth of which are beyond current technology. Most of
he nucleoside-modified RNA utilized in the present
tudy contained one type of modification amassing
25% of the total nucleotides in the RNA. Because the
atio of any one particular modified nucleoside, though
ariable, is much lower than 25% in native RNAs, we
sked what is the minimal frequency of any one partic-
lar modified nucleoside that is sufficient to limit the
mmunostimulatory potential of RNA. To answer this
uestion, two approaches were used to generate RNA
ith limited numbers of modified nucleosides. First, we
ranscribed RNA in vitro in the presence of decreasing
mounts of m6A, Ψ, or m5C and increasing amounts of
he corresponding unmodified NTPs. We expected the
ncorporation of modified nucleoside phosphates into
NA to be proportional to the ratio contained in the
ranscription reaction, because prior RNA yields ob-
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169Figure 3. Cytokine Production by RNA-Transfected DCs
MDDC (A and C), IFN-α MDDCs (B), and primary DC1 and DC2 (D) were treated for 8–16 hr with lipofectin alone or complexed with R-848 (1
g/ml) or the indicated RNA (5 g/ml). Modified nucleosides present in RNA-1571 are noted. TNF-α, IL-12(p70), and IFN-α were measured in
the supernatant by ELISA. Mean values ± SEM are shown. The results are representative of ten (A and C), four (B), and six (D) independent
experiments. N.D., not determined.tained with T7 RNAP suggested the enzyme utilizes
NTPs of m6A, Ψ, or m5C almost as efficiently as the
basic NTPs. HPLC analysis confirmed this notion,
showing for example, that after digestion of RNA tran-
scribed in the presence of UTP:ΨTP in a 50:50 ratio,
nearly equal amounts of incorporated UMP and ΨMP
were released (Figure 5A). When RNA-1571 with increas-
ing amounts of modified nucleoside content were
transfected into MDDCs, we detected that the pres-
ence of an increasing amount of modified nucleosides
proportionally inhibited the capacity of RNA to induce
TNF-α (Figure 5B). The presence of 0.2%–0.4% m6A,
Ψ, or m5C in the RNA, which corresponds to approxi-
mately three to six modified nucleosides per one mole-
cule of the 1571 nt-long RNA, was sufficient to cause
detectable inhibition of cytokine secretion (Figure 5B).
When RNAs with modified nucleoside levels of 1.7%–
3.2%, which correspond to 14–29 modifications per
molecule, were tested, the RNA could maintain only
half of its capacity to induce expression of TNF-α.
When similar transfection experiments were performed
on TLR-expressing 293 cells, usually a higher percent(w2.5%) of modified nucleoside content was required
to inhibit RNA-mediated signaling events (data not shown).
In the second approach, we utilized chemically syn-
thesized 21-mer ORNs with phosphodiester inter-
nucleotide linkages and 5# monophosphate and iden-
tical primary sequences but with modified nucleosides
such as m5C, Ψ, or 2#-O-methyl-U (Um) in a single posi-
tion (Figure 6A). Results obtained after transfection of
MDDCs with the synthetic ORNs demonstrated that
short unmodified ORNs were capable of inducing sig-
nificant TNF-α secretion, but the presence of a single
nucleoside modification was sufficient to abolish this
effect (Figure 6B). Repeating the experiments on TLR-
transformed 293 cells expressing TLR3-targeted siRNA,
we found that control ORN induced 293-hTLR8 cells to
secrete IL-8, whereas those containing modified nucle-
osides did not. When testing ORNs on hTLR3- or hTLR7-
expressing cell lines, however, we saw no IL-8 secretion
under any conditions (data not shown). Finally, by using
Northern assay, we tested the 21-mer chemically syn-
thesized ORNs along with 31-mer in vitro transcripts for
their ability to induce TNF-α mRNA in MDDCs. ORN5
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MDDCs were treated for 20 hr with lipofectin
alone or complexed with R-848 (1 g/ml) or
the indicated RNA (5 g/ml). Modified nucle-
osides present in RNA-1571 are indicated.
(A) CD83 and HLA-DR staining is shown.
(B) TNF-α was measured in the supernatants
by ELISA (the asterisk represents cells that
were cultured in 30-fold larger than usual
volume of medium for flow cytometry). Mean
fluorescence of CD80 and CD86 was deter-
mined by flow cytometry. Data are represen-
tative of four independent experiments.and ORN6 (31-mers) caused robust induction, whereas s
pthe 21-mer ORN1 control induced less TNF-α mRNA,
although still well detectable, particularly in cells ex-
posed to the protein synthesis inhibitor cycloheximide, D
which is also known to block degradation of selected
mRNAs. More importantly, ORNs containing a single W
dmodified nucleoside induced less TNF-α mRNA, and
consistently, ORN2-Um, the 2#-O-methylated ORN, was p
mthe least stimulatory (Figure 6C). Taken together, these
results demonstrate that RNA-mediated immune stimu- n
ulation is suppressed proportionally by the number of
modified nucleosides present in RNA. Modification, n
mwhen present in a single or very few positions, depend-
ing on the length of RNA, was sufficient to inhibit the ttimulatory effect of RNA on MDDC and 293 cells ex-
ressing individual TLRs.
iscussion
e demonstrate here that a variety of natural RNAs had
ifferent capacities to activate immune cells. The most
otent RNAs were those that had the least number of
odified nucleosides; therefore, we hypothesize that
ucleoside modification suppresses the immune-stim-
latory effect of RNA. In a quest to prove this, several
ovel lines of evidence were discovered about RNA-
ediated immune activation. Initially, we established
hat RNA is a ligand for human TLR7. Next, by using
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171Figure 5. Analyzing RNA Containing Different
Amounts of Modified Nucleosides
Capped RNA-1571 containing m6A, Ψ, or
m5C was transcribed under conditions in
which the relative ratio of m6ATP, ΨTP, or
m5CTP to the corresponding unmodified
NTP was 0%, 1%, 10%, 50%, 90%, 99%,
and 100%.
(A) All transcripts were digested to mono-
phosphates and analyzed by reversed-
phase HPLC to determine the relative
amount of modified nucleoside incorpora-
tion. For simplicity, only symbols for the nu-
cleosides are shown. Representative absor-
bance profiles obtained by RNA transcribed
in the presence of pseudouridine- and uri-
dine-triphosphates (Ψ:U) at the indicated ra-
tios are shown. Elution times are noted for
3#-monophosphates of pseudouridine (Ψ),
cytidine (C), guanosine (G), uridine (U),
7-methylguanosine (m7G), and adenoside (A).
(B) Modified nucleoside content of RNA-
1571. The expected percentage of m6A, Ψ,
or m5C in RNA-1571 was calculated based
on the relative amount of modified NTP in
the transcription reaction and the nucleoside
composition of RNA-1571 (expected percen-
tage). The values for measured modified nu-
cleoside content (in percentage) were deter-
mined based on relative values obtained
after quantitation of the HPLC chromato-
grams. Based on these measured values and
on the nucleoside content of RNA-1571 (A:
505, U: 451, C: 273, and G: 342), the number
of m6A, Ψ ,or m5C per molecule of RNA-
1571 was calculated. “a” represents values
(%) for m6ATP, ΨTP, and m5CTP relative to ATP UTP and CTP, respectively. “b” represents values for m6A, Ψ, and m5C monophosphates
relative to all NMPs.
(C) MDDCs were transfected with lipofectin-complexed capped RNA-1571 (5 g/ml) containing the indicated amount of m6A, Ψ, or m5C.
After 8 hr, TNF-α was measured in the supernatants by ELISA. Data are expressed as relative inhibition of TNF-α. Mean values ± SEM
obtained in three independent experiments are shown. The number of m6A, Ψ, or m5C per molecule of RNA-1571 was calculated as indicated
in (B).RNA bearing modified nucleosides such as m5C, m5U,
s2U, m6A,Ψ, or 2#-O-methyl-U, all constituents of natu-
ral RNA, we showed that modifying U, A, and C nucleo-
sides, in general, suppresses the capacity of RNA to
activate cytokine-generated DCs, as measured by secre-
tion of TNF-α and IL-12 and by expression of CD80,
CD83, CD86, and HLA-DR. Interestingly, only uridine
modifications, such as m5U, s2U, or Ψ, but not m5C
or m6A, could abolish the capacity of RNA to activate
primary, blood-derived DCs. Distinct TLRs responded
differently to RNA containing different modified nucleo-
sides. RNA with m6A and s2U modifications did not
activate TLR3, and those with m5C, m5U, s2U, m6A, or
Ψ did not activate TLR7 or TLR8, whereas unmodified
RNA could activate all these human TLRs. Finally, we
show that RNA-mediated immune stimulation is sup-
pressed proportionally with the number of modified nu-
cleosides present in RNA and that even a few modifica-
tions are sufficient to exert a suppressive effect.
Nucleoside modification is the foundation of the most
ancient “immune” mechanism. Bacteria methylate se-
lected nucleosides in their own genome, which enables
them to distinguish and destroy an invader’s unmodi-
fied DNA with restriction enzymes. During evolution,
the discrimination between host and pathogen basedon characteristics of DNA methylation remains an im-
portant component of the immune system. In mamma-
lian DNA, cytosines in CpG motifs are mostly methyl-
ated, but the lack of such modification in the genomes
of microbial pathogens is recognized by TLR9, which
then mediates the induction of the mammalian innate
immune response (Hemmi et al., 2000).
Despite the fact that the immune stimulatory activity
of RNA was discovered decades before such was iden-
tified for DNA and that RNA contains numerous modi-
fied nucleosides (Rozenski et al., 1999), the effect of
nucleoside modifications on RNA immunity has not
been explored. From the standpoint of immune activa-
tion, RNA and DNA share many characteristics. We
have shown that RNA, similarly to DNA, is more immu-
nogenic when derived from bacteria than from mamma-
lian cells (Figures 1 and 2C) (Koski et al., 2004). Similar
to mammalian DNA, mammalian RNA also exerts a lim-
ited but detectable level of immune activation (Figure
1). Others have reported that mammalian RNA induces
IFN-α when delivered to immune cells (Diebold et al.,
2004). To explain why mammalian RNAs are immuno-
genic, it was reasoned that in those experiments trans-
fected RNA entered the endosomal compartments of
immune cells, therefore the immune system might
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172Figure 6. TNF-α Expression by RNA-Transfected DCs
(A) Sequences of oligoribonucleotides (ORNs) synthesized chemically (ORN1-4) or transcribed in vitro (ORN5-6) are shown. Positions of
modified nucleosides Um (2#-O-methyluridine), m5C, and Ψ are highlighted. Human MDDCs were transfected with lipofectin alone (medium),
R-848 (1 g/ml), or with the indicated RNA (5 g/ml) complexed with lipofectin. Where noted, cells were treated with 2.5 g/ml cycloheximide
(CHX). After 8 hr incubation, TNF-α was measured in the supernatant by ELISA (B). Mean values ± SEM are shown. The results are representa-
tive of three independent experiments. RNA isolated from the cells were analyzed by Northern blot (C).discriminate between self and nonself RNA based on o
ccellular location rather than some unique pathogen-
associated molecular pattern (Crozat and Beutler,
m2004). It has been shown, however, that the human in-
nate immune system can also discriminate between e
dmolecular features of eukaryotic and bacterial mRNA
and recognize mRNA devoid of polyA-tail as stimula- a
etory (Koski et al., 2004). In this report, we observed po-
tent immune stimulation with bacterial, but not with h
mmammalian, total RNA and concluded that this was due
to the difference in their modified nucleoside content. t
cThis is supported by the observation that the major
mass of total RNA is rRNA, and modified nucleosides r
sare abundant in mammalian, but not in bacterial, rRNA:
3% versus 0.8% (Bachellerie and Cavaille, 1998). We t
also observed that suppression of RNA-mediated im-
mune stimulation correlated with the level of this differ- t
mence in modified nucleoside content (Figure 5C). The
present study now identifies nucleoside modification as s
sa novel feature of RNA recognized by the innate im-
mune system, specifically by TLR3, TLR7, and TLR8 M
t(Figure 2). We observed earlier that RNA from necrotic
cells activated DCs, whereas RNA from apoptotic cells t
edid not (Kariko et al., 2004). Based on the results pre-
sented in this report, we now propose that mammalian m
lRNA, especially the least-modified mtRNA, likely con-
tributed to the observed effect. The immune potential
oof mammalian RNA might also explain why degradation
of RNA during apoptosis is so critical. Fragmentation of d
agenomic DNA is a well-established process and used
consistently as a technique to define apoptosis itself. u
mAlthough less described, a well-orchestrated degrada-
tion of cellular RNA also occurs in apoptotic, but not f
lnecrotic, cells. Interestingly, the most immunogenic
mtRNA degrades at a very early stage of apoptosis s
i(Crawford et al., 1997), hours before the breakdown of
cytoplasmic RNA, DNA laddering (Houge et al., 1995), Ir morphological changes associated with apoptosis
ould be detected.
Both RNA and DNA are central immunogenic deter-
inants in the autoimmune disease of systemic lupus
rythematosus (SLE), which is characterized by pro-
uction of autoantibodies directed against DNA, RNA,
nd proteins associated with nucleic acids (Ronnblom
t al., 2003). In the development of SLE, studies now
ave established the involvement of TLR9 activation by
ammalian DNA that bears hypomethylated CpG mo-
ifs (Boule et al., 2004). Another prominent target mole-
ule in SLE is U1 small nuclear RNA, which has been
ecently shown to activate TLR3 (Hoffman et al., 2004),
uggesting the potential involvement of an RNA-sensi-
ive TLR in the disease process.
Nucleosides in native RNA become modified post-
ranscriptionally as part of their maturation process. Al-
ost one hundred different types of modified nucleo-
ides have been identified in RNA, but the physiological
ignificance of these alterations is not well understood.
ost of the modifications occur nonrandomly at posi-
ions conserved across diverse species, implying that
hey are important. Surprisingly, however, even the
xtensively modified tRNA could function without any
odification (Sampson and Uhlenbeck, 1988), thus
eaving the role of nucleoside modification very puzzling.
Pseudouridine is the most abundant modified nucle-
side in RNA. It is generated by isomerization of uri-
ines. We have demonstrated here that pseudouridine
long with the other uridine modifications m5U and s2U
niquely suppress the capacity of RNA to activate pri-
ary DCs (Figure 3D). This finding implies that unmodi-
ied uridine probably contributes to the immune stimu-
atory action of RNA. Indeed, several points of evidence
upport this suggestion. In an earlier study, poly(U) was
dentified as the only homopolymer capable of inducing
L-12 in primed DCs (Koski et al., 2004). By using DCs
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173from TLR7 null mice, Diebold et al. identified TLR7 as
the responding receptor for poly(U) treatment (Diebold
et al., 2004). Others have shown that even nucleoside
mixtures with uridine are sufficient to stimulate PBMCs
to secrete TNF-α (Heil et al., 2004). Of interest, we did
not find that poly(U) or any other RNA homopolymer
activated primary DCs or human TLR3, TLR7, or TLR8
when transformed 293 cells expressing these receptors
were used for testing. Presence of Ψ in RNA promotes
base stacking, thereby stabilizing RNA duplex regions
(Charette and Gray, 2000), which might explain why
Ψ-modified RNA could potently activate TLR3 (Figure 2B).
N6-methyladenosine (m6A) is the only base-modified
nucleoside that is present in all RNA types, including
rRNA, tRNA, and snRNA, as well as in mRNAs of cellu-
lar and viral origins. The methylation in m6A interferes
with Watson-Crick base pairing, thus, its presence de-
stabilizes RNA duplexes (Kierzek and Kierzek, 2003).
This characteristic of m6A might explain why RNA con-
taining m6A did not stimulate TLR3 (Figure 2B). m6A is
present in mRNA of mammalian cells and RNA of
viruses that replicate in the nucleus such as influenza,
adenovirus, HSV, SV40, and RSV (Bokar and Rottman,
1998). In general, m6A modifications were found in-
ternally, mostly in coding sequences, and viral mRNA
usually contained significantly more m6A than cellular
mRNA (Bokar and Rottman, 1998). Interestingly, Rous
sarcoma virus replicated similarly with and without m6A
when tested in cell culture (Kane and Beemon, 1987),
therefore no function could be assigned to m6A in this
viral mRNA. It is tempting to speculate that the pres-
ence of m6A in viral RNA might serve the virus by allow-
ing it to avoid immune activation. This suggestion is
strengthened by considering that the frequency of m6A
modifications found in viral mRNAs, up to eight per a
1.8 kb-long segment of influenza RNA (Narayan et al.,
1987), is sufficient to suppress the capacity of RNA to
activate DCs (Figure 5). Because those early studies
with viruses were performed in cell culture and not in
animals, the immune suppressive effect of m6A might
have been missed.
RNA containing either m6A or m5C stimulated pri-
mary DC1 and DC2 as potently as the corresponding
nonmodified RNA (Figure 3D). This was an unexpected
finding, because DC2 express only TLR7 (Ito et al.,
2002; Matsumoto et al., 2003) and thus resemble 293-
hTLR7 cells that did not respond to any of the modified
RNA (Figure 2B). Because all tested RNA were deliv-
ered by transfection to the cells, where they could in-
teract with many different RNA binding proteins, it is
possible an RNA receptor is uniquely present in primary
DCs, but not in 293 cells or MDDCs. Such an RNA sen-
sor could likely recognize U-rich RNA patterns even in
the presence of the m6A and m5C nucleoside residues,
but not when the U residues are masked by modifica-
tions. Support for this hypothesis was provided by the
observations that RNA containing both m6A and Ψ
modifications on the same strand did not activate DC1
or DC2, whereas mixtures of RNA containing either
m6A or Ψmodification on separate strands potently ac-
tivated these cells (Figure 3D). In this regard, there are
already examples for single- and double-stranded
RNA-responsive cytoplasmic receptors such as FADD,RIG-1, and PKR that function in the innate immune sys-
tem independently from TLRs (Sen and Sarkar, 2005).
By using TLR7-expressing cell lines, we demonstrate
(Figure 2) that in vitro-transcribed RNA and bacterial
RNA, but not dsRNA, are ligands for human TLR7. This
finding is in discordance with results obtained by Heil
et al. (2004), who showed that human TLR7 was nonre-
sponsive to RNA oligomers with phosphorothioate link-
age. Differences in the stimulating RNA, such as long
RNA versus short ORNs with phosphorothioate linkage,
likely account for the conflicting result. We observed
that all in vitro-transcribed RNAs, regardless of their
primary sequence, as well as bacterial RNA activated
TLR7 expressing 293 cells, demonstrating that natural
RNA is a ligand for this receptor.
In summary, we demonstrate that selected natural
RNA isolated from mammalian and bacterial cells and
RNA transcribed in vitro or synthesized chemically acti-
vate human DCs and stably transformed 293 cells ex-
pressing human TLR3, TLR7, or TLR8. Such activation
was reduced or completely eliminated with RNA con-
taining naturally occurring modified nucleosides, such
as m5C, m6A, m5U, pseudouridine, or 2#-O-methyl-U.
Insights gained from this study could advance our un-
derstanding of autoimmune diseases where nucleic
acids play a prominent role in the pathogenesis, deter-
mine a role for nucleoside modifications in viral RNA,
and give future directions into the design of therapeu-
tic RNAs.
Experimental Procedures
Plasmids and Reagents
Plasmids pTEVluc (D. Gallie, UC Riverside), pT7T3D-MART-1
(ATCC, Manassas, VA), pUNO-hTLR3 (InvivoGen, San Diego, CA),
and pSVren (Kariko et al., 2004) were obtained. Human TLR3-spe-
cific siRNA, pTLR3-sh was constructed by inserting synthetic ODN-
encoding shRNA with 20 nt-long homology to human TLR3 (nt 703–
722, accession: NM_003265) into plasmid pSilencer 4.1-CMV-neo
(Ambion, Austin, TX). pCMV-hTLR3 was obtained by first cloning
hTLR3-specific PCR product (nt 80–2887; accession NM_003265)
into pCRII-TOPO (Invitrogen, Carlsbad, CA), then released with
NheI-HindIII cutting and subcloning to the corresponding sites of
pcDNA3.1 (Invitrogen). Cells were treated with the following re-
agents: LPS (E. coli 055:B5) (Sigma Chemical Co, St. Louis, MO),
CpG ODN-2006, and R-848 (InvivoGen).
Cells and Cell Culture
Human embryonic kidney 293 cells (ATCC) were propagated in
DMEM supplemented with glutamine (Invitrogen) and 10% FCS
(Hyclone, Ogden, UT) (complete medium). 293-hTLR3 and 293
pUNO null cell lines were generated by transforming 293 cells with
pUNO-hTLR3 and pUNO null. Cell lines 293-hTLR7, 293-hTLR8,
and 293-hTLR9 (InvivoGen) were grown in complete medium sup-
plemented with blasticidin (10 g/ml) (Invivogen). Cell lines 293-
ELAM-luc and TLR7-293 (M. Lamphier, Eisai Research Institute, An-
dover MA) and TLR3-293 cells were cultured as described (Kariko
et al., 2004). Cell lines 293, 293-hTLR7, and 293-hTLR8 were stably
transfected with pTLR3-sh and selected with G-418 (400 g/ml)
(Invitrogen). Neo-resistant colonies were screened, and only those
that did not express TLR3, determined as lack of IL-8 secretion in
response to poly(I):(C), were used. Cell lines were used as soon as
possible, because shRNA-mediated suppression of TLR3 became
leaky over time. Leukopheresis samples were obtained from HIV-
uninfected volunteers through an IRB-approved protocol. DCs
were produced as described previously and treated with GM-CSF
(50 ng/ml) + IL-4 (100 ng/ml) (Weissman et al., 2000) or IFN-α (1000
U/ml) (Santini et al., 2000) (R&D Systems, Minneapolis, MN) in AIM
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174V medium (Invitrogen). Primary myeloid and plasmacytoid DCs 9
(DC1 and DC2) were obtained from peripheral blood by using O
BDCA-1 and BDCA-4 cell isolation kits (Miltenyi Biotec Auburn, w
CA), respectively. s
t
RNA p
In Vitro-Transcribed RNA
By using in vitro transcription assays (MessageMachine and Mega- R
Script kits; Ambion), the following long RNAs were generated by m
T7 RNAP as described (Kariko et al., 1998) (note: the names of h
templates are in parentheses), the number in the name of the RNA f
specifies the length: RNA-1866 (NdeI-linearized pTEVluc) encodes c
firefly luciferase and a 50 nt-long polyA-tail, RNA-1571 (SspI-linear- 1
ized pSVren) encodes Renilla luciferase, RNA-730 (HindIII-linear- a
ized pT7T3D-MART-1) encodes the human melanoma antigen i
MART-1, RNA-713 (EcoRI-linearized pT7T3D-MART-1) corresponds q
to antisense sequence of MART-1, and RNA-497 (BglII-linearized
pCMV-hTLR3) encodes a partial 5# fragment of hTLR3. To obtain A
RNA bearing nucleoside modification, the transcription reaction D
was assembled with the replacement of one (or two) of the basic a
NTPs with the corresponding triphosphate-derivative(s) of the s
modified nucleotide 5-methylcytidine, 5-methyluridine, 2-thiouri- o
dine, N6-methyladenosine, or pseudouridine (TriLink, San Diego, c
CA). In each transcription reaction, all four nucleotides or their de- e
rivatives were present in equimolar (7.5 mM) concentration. In se-
lected experiments, 6 mM m7GpppG cap analog (New England N
BioLabs, Beverly, MA) was also included to obtain capped RNA. To R
obtain RNA containing increasing amounts of m6A, Ψ, or m5C, the t
transcription reaction was performed in a reaction mix in which the w
ratio of one particular modified NTP relative to the corresponding t
unmodified NTP was 0%, 1%, 10%, 50%, 90%, 99%, and 100%. By w
using DNA oligodeoxynucleotide templates and T7 RNAP (Silencer
i
siRNA construction kit, Ambion), ORN5 and ORN6 were generated.
fNatural and Synthetic RNA
A
Mitochondria were isolated from outdated platelets (obtained from
the University of Pennsylvania Blood Bank under an IRB approved
protocol) by using a fractionation lyses procedure as described by
Sthe manufacturer (Mitochondria Isolation Kit; Pierce, Rockford, IL).
SRNA was isolated from the purified mitochondria, cytoplasmic and
anuclear fractions of 293 cells, unfractioned 293 cells, rat liver, mouse
1cell line TUBO, and DH5α strain of E. coli by Master Blaster (Bio-
Rad, Hercules, CA). Bovine tRNA, wheat tRNA, yeast tRNA, E. coli
AtRNA, poly(A)+ mRNA from mouse heart, and poly(I):(C) were pur-
chased from Sigma; total RNA from human spleen and E. coli RNA
Twere purchased from Ambion. Oligoribonucleotide 5#-monophos-
Aphates were synthesized chemically (Dharmacon, Lafayette, CO).
Aliquots of RNA samples were incubated in the presence of
Benzonase nuclease (1 U per 5 l of RNA at 1 g/l for 1 hr) (Nova- R
gen, Madison, WI). Aliquots of RNA-730 were digested with alkaline R
phosphatase (New England Biolab). Generally, RNA samples were A
analyzed by denaturing agarose or polyacrylamide gel electropho- P
resis for quality assurance. Assays for LPS in RNA preparations
using the Limulus Amebocyte Lysate gel clot assay were negative R
with a sensitivity of 3 pg/ml (University of Pennsylvania, Core Fa-
cility). A
RHPLC Analysis
T
Nucleoside monophosphates were separated and visualized via
BHPLC (Greenwood and Gentry, 2002). Briefly, first to release free
gnucleoside 3#-monophosphates, 5 g aliquots of RNA were di-
agested with 0.1 U RNase T2 (Invitrogen) in 10 l of 50 mM NaOAc
Dand 2 mM EDTA buffer (pH 4.5) overnight, then the samples were
injected into an Agilent 1100 HPLC by using a Waters Symmetry B
C18 column (Waters, Milford, MA). Buffer A consisted of 30 mM o
KH2PO4 and 10 mM tetraethylammonium phosphate (PicA reagent, E
Waters), pH 6.0. Buffer B was acetonitrile. At a flow rate of 1 mL/ A
min, a gradient from 100% buffer A to 30% buffer B was run over B
60 min. Nucleotides were detected by using a photodiode array at R
254 nm. Identities were verified by retention times and spectra. a
Relative percentage of modified versus the corresponding unmodi- g
fied nucleosides in RNA was determined for each transcript.
C
wTreatment of Cells
CParental 293, 293-hTLR7, and 293-hTLR8 cells, all expressing
TLR3-specific siRNA, and 293-hTLR9, TLR3-293 were seeded into S6-well plates (5 × 104 cells/well) and cultured without antibiotics.
n the subsequent day, the cells were exposed to R-848 or RNA
ith prior complexing to lipofectin (Invitrogen) as previously de-
cribed (Kariko et al., 1998). The RNA was removed after 1 hr, and
he cells were further incubated in complete medium for 7 hr. Su-
ernatants were collected for IL-8 measurement.
DCs in 96-well plates (w1.1 × 105 cells/well) were treated with
-848, lipofectin alone, or complexed with RNA for 1 hr when the
edium was replaced by fresh medium. Cells and medium were
arvested at the end of an 8–20 hr incubation; cells were harvested
or either RNA isolation or flow cytometry, whereas the collected
ulture medium was subjected to cytokine ELISA. The levels of IL-
2 (p70) (BD Biosciences Pharmingen, San Diego, CA), IFN-α, TNF-α,
nd IL-8 (Biosource International, Camarillo, CA) were measured
n supernatants by ELISA. Cultures were performed in triplicate to
uadruplicate and measured in duplicate.
nalysis of DC Activation
Cs treated as described above were analyzed by flow cytometry
fter 20 hr. DCs were stained with CD83-phycoerythrin mAb (Re-
earch Diagnostics Inc, Flanders, NJ), HLA-DR-Cy5PE, and CD80
r CD86-fluorescein isothiocyanate mAb and analyzed on a FACS-
alibur flow cytometer by using CellQuest software (BD Biosci-
nces).
orthern Blot Analysis
NA was isolated from MDDCs after an 8 hr incubation following
reatment as described above. Where noted, cells were treated
ith 2.5 g/ml cycloheximide (Sigma) 30 min prior to the stimula-
ion and throughout the entire length of incubation. RNA samples
ere processed and analyzed on Northern blots as described (Kar-
ko et al., 2004) by using human TNF-α and GAPDH probes derived
rom plasmids (pE4 and pHcGAP, respectively) obtained from
TCC.
upplemental Data
upplemental Data include one figure and are available with this
rticle online at http://www.immunity.com/cgi/content/full/23/2/
65/DC1/.
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